首页> 外文期刊>Nutrients >Patients Undergoing Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation Exhibit Depleted Vitamin C Status in Association with Febrile Neutropenia
【24h】

Patients Undergoing Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation Exhibit Depleted Vitamin C Status in Association with Febrile Neutropenia

机译:接受髓鞘化化疗和造血干细胞移植的患者表现出与Febrile Neutropenia相关的耗尽维生素C状态

获取原文
获取外文期刊封面目录资料

摘要

Patients undergoing myeloablative chemotherapy and hematopoietic stem cell transplantation (HSCT) experience profound neutropenia and vulnerability to infection. Previous research has indicated that patients with infections have depleted vitamin C status. In this study, we recruited 38 patients with hematopoietic cancer who were undergoing conditioning chemotherapy and HSCT. Blood samples were collected prior to transplantation, at one week, two weeks and four weeks following transplantation. Vitamin C status and biomarkers of inflammation (C-reactive protein) and oxidative stress (protein carbonyls and thiobarbituric acid reactive substances) were assessed in association with febrile neutropenia. The vitamin C status of the study participants decreased from 44 ± 7 μmol/L to 29 ± 5 μmol/L by week one ( p = 0.001) and 19 ± 6 μmol/L by week two ( p 0.001), by which time all of the participants had undergone a febrile episode. By week four, vitamin C status had increased to 37 ± 10 μmol/L ( p = 0.1). Pre-transplantation, the cohort comprised 19% with hypovitaminosis C (i.e., 23 μmol/L) and 8% with deficiency (i.e., 11 μmol/L). At week one, those with hypovitaminosis C had increased to 38%, and at week two, 72% had hypovitaminosis C, and 34% had outright deficiency. C-reactive protein concentrations increased from 3.5 ± 1.8 mg/L to 20 ± 11 mg/L at week one ( p = 0.002), and 119 ± 25 mg/L at week two ( p 0.001), corresponding to the development of febrile neutropenia in the patients. By week four, these values had dropped to 17 ± 8 mg/L ( p 0.001). There was a significant inverse correlation between C-reactive protein concentrations and vitamin C status ( r = ?0.424, p 0.001). Lipid oxidation (thiobarbituric acid reactive substances (TBARS)) increased significantly from 2.0 ± 0.3 μmol/L at baseline to 3.3 ± 0.6 μmol/L by week one ( p 0.001), and remained elevated at week two ( p = 0.003), returning to baseline concentrations by week four ( p = 0.3). Overall, the lowest mean vitamin C values (recorded at week two) corresponded with the highest mean C-reactive protein values and lowest mean neutrophil counts. Thus, depleted vitamin C status in the HSCT patients coincides with febrile neutropenia and elevated inflammation and oxidative stress.
机译:患有髓鞘化疗和造血干细胞移植(HSCT)的患者经历深刻的中性粒细胞减少和脆弱性对感染。以前的研究表明,感染的患者具有耗尽的维生素C状态。在本研究中,我们招募了38例患有调理化疗和HSCT的造血癌患者。在移植前,在移植后一周,两周和四周内收集血样。与Febrier Neutropenia相关联,评估了炎症(C反应蛋白)和氧化应激(蛋白质羰基和硫酰比酸反应性物质)的维生素C状态和生物标志物。研究参与者的维生素C状态从一周(P <0.001)到19±6μmol/ L的一周(p = 0.001)和19±6μmol/ l的44±7μmol/ l至29±5μmol/ l。所有参与者都经历了一集发作。截至第四周,维生素C状态增加至37±10μmol/ L(P = 0.1)。预移植,群组占18%的钙氨基胺,C(即<23μmol/ L)和8%的缺乏(即<11μmol/ L)。一周,含钙胺素C的人数增加到38%,并且在第二周,72%的患有下钙胺蛋白症C,34%的缺乏症。 C-反应性蛋白浓度在一周(P = 0.002)时从3.5±1.8mg / L增加到20±11 mg / L,并在两周(P <0.001)时119±25 mg / L,对应于开发在患者的Febrile Neutropenia。在第四周,这些值下降至17±8 mg / L(P <0.001)。 C-反应性蛋白质浓度和维生素C状态之间存在显着的反比异性(R = 0.424,P <0.001)。脂质氧化(硫氨基甲酸乙酸反应性物质(TBARS))在基线的2.0±0.3μmol/ L上显着增加至3.3±0.6μmol/ L(p <0.001),并在第二周保持升高(p = 0.003),返回基线浓度(第四周(P = 0.3)。总体而言,最低平均维生素C值(第两周记录)对应于最高平均C-反应蛋白值和最低平均中性粒细胞计数。因此,HSCT患者中的耗尽维生素C状态与Febrile Neveropenia和炎症和氧化应激升高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号